Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi Elitek approved

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Sanofi-Synthelabo's recombinant urate-oxidase enzyme Elitek (rasburicase) is approved July 12 for "initial management of plasma uric acid levels in pediatric patients with leukemia, lymphoma and solid tumor malignancies who are receiving anti-cancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid." Phase IV commitments include development of a validated immunogenicity assay, collecting serum samples from all study patients until the assay is developed, a study in at least 150 patients assessing repetitive treatment with rasburicase, and a study comparing the approved dose and schedule of rasburicase with a regimen of sequential rasburicase and allopurinol, a competing product indicated for hyperuricemia. Sanofi plans to launch Elitek in mid-August. The firm projects worldwide sales will reach EUR 100 mil. in 2005; rasburicase was launched in Europe in 2001 under the brand Fasturtec

You may also be interested in...



QUOTED. 25 February 2021. Adam Saltman.

A recent FDA action plan on artificial intelligence and machine learning (AI/ML) medical software could encourage more to jump in, said Eko Chief Medical Officer Adam Saltman.

Daiichi's Novel EZH Candidate Moves Ahead With New Consortium Trial

Japanese major links with new partners in European consortium to progress first-in-class molecule for multiple hematological malignancies.

J&J's COVID-19 Vaccine May Face Efficacy Comparison Questions At US FDA Panel Review

Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel